facebook tracking

The Future of Biological Regulation in India: Biosimilars, CAR-T, AI & Advanced Therapies

tag icon Regulation/Guidelines
category icon Biological,
Share on X, Facebook, Linkedin

Summary: India’s Biological Regulatory landscape is at an inflection point. The country that pioneered affordable Biosimilar access, built one of the…

India’s Biological Regulatory landscape is at an inflection point. The country that pioneered affordable Biosimilar access, built one of the world’s largest vaccine manufacturing ecosystems, and established the framework for recombinant Biological oversight is now navigating a new wave of regulatory complexity — driven by CAR-T cell therapies, personalised medicine, AI-assisted Biological development, and the rapid evolution of advanced therapy medicinal products (ATMPs).

CDSCO, the RCGM, DBT, and the broader Indian regulatory community are responding with draft guideline revisions, new advisory committee frameworks, and regulatory modernisation initiatives that signal a fundamental transformation of how advanced Biologicals will be regulated in India over the next decade.

1. Draft 2025 Similar Biologics Guidelines Revision

The most immediately impactful regulatory development is the ongoing revision of the Similar Biologics Guidelines — India’s primary biosimilar development and approval framework, originally published in 2012 and updated in 2016. The draft 2025 revision, anticipated for formal notification in 2026, is expected to introduce:

  1. Alignment with WHO biosimilar guidelines (WHO TRS 1043, 2022) — bringing India’s comparability expectations closer to global standards
  2. Expanded guidance on analytical similarity — recognising advances in higher-order structure characterisation that can reduce the clinical data burden for highly characterised biosimilars
  3. Risk-based clinical waiver provisions — allowing waiver of certain PK/PD or efficacy studies where analytical and non-clinical comparability is comprehensive
  4. Updated guidance on extrapolation of indications — clarifying standards for extending biosimilar approval across multiple indications of the reference biologic
  5. More granular provisions for mAb biosimilars — reflecting the growth of India’s mAb biosimilar pipeline

The draft guidelines represent a maturation of India’s biosimilar regulatory framework — moving from a prescriptive, stepwise approach to a science and risk-based model that rewards analytical characterisation quality.

2. CAR-T and Advanced Cell and Gene Therapy: Regulatory Evolution

India’s first domestic CAR-T cell therapy — NexCAR19 (actalycabtagene autoleucel) — was approved by CDSCO in October 2023, marking a watershed moment in India’s advanced therapy regulation. This approval demonstrated that India could evaluate and approve complex autologous cell therapies with a credible scientific framework and has catalysed significant regulatory thinking about systematically governing CAR-T and related ATMPs.

Several regulatory developments are anticipated:

  • CDSCO-specific ATMP guidelines — India currently evaluates ATMPs under the general New Drug framework; dedicated ATMP guidelines modelled on EMA’s ATMP Regulation are under consideration
  • Allogeneic CAR-T regulatory clarity — NexCAR19 was autologous; a specific pathway for allogeneic (off-the-shelf) CAR-T products requires dedicated guidance
  • Hospital exemption framework — EMA-style provisions for hospital-pharmacy-prepared ATMPs for individual patients are being discussed in Indian regulatory circles
  • Formalised multi-authority coordination — between CDSCO, RCGM, DBT, IBSC, and transplantation authorities for complex gene-modified cell therapies

3. Gene Therapy: An Emerging Frontier

In vivo gene therapies (AAV-based, LNP-delivered) and gene editing products challenge existing regulatory categories in India. CDSCO has not yet published specific guidance for in vivo gene therapy products — these are currently evaluated under the New Drug framework with RCGM and GEAC involvement. As the global pipeline matures and India-based gene therapy programmes develop, dedicated guidance will become necessary. Key future regulatory considerations include:

  • Long-term follow-up requirements — gene therapy products require follow-up periods of 15 years or more; India’s post-marketing surveillance framework will need adaptation
  • Vector manufacturing oversight — AAV and lentiviral vector manufacturing involves complex rDNA and biosafety considerations requiring RCGM and IBSC coordination
  • Germline editing prohibition — India currently prohibits heritable germline modifications; this is expected to be codified explicitly in future regulations

4. Artificial Intelligence in Biological Development and Regulation

4.1 AI in Biological Product Development

AI-driven protein design platforms are accelerating antibody and Biosimilar development — enabling in silico optimisation of immunogenicity, stability, and potency profiles. India’s growing biotechnology sector in Bengaluru and Hyderabad is beginning to leverage these platforms. CDSCO will increasingly encounter dossiers incorporating AI-generated data — requiring a regulatory stance on the evidentiary value and validation requirements for AI-derived evidence. The ICH M14 guideline on AI/ML in drug development, currently under development, will provide the international framework India is expected to adopt.

4.2 AI in Regulatory Review and Pharmacovigilance

CDSCO has initiated exploratory work on AI tools for dossier review and adverse event signal detection through PvPI. AI-assisted review — analysing large clinical datasets, detecting dossier inconsistencies, and prioritising safety signals — has the potential to significantly accelerate review timelines and improve the quality of regulatory decisions.

5. India as a Global Biologics Hub: The Strategic Opportunity

India’s ambition to become a global biologics manufacturing hub is increasingly credible. Structural factors supporting this trajectory include:

  • Deep scientific talent pool — India produces over 1.5 million science graduates annually, with growing biotechnology specialisation
  • Established biosimilar manufacturing infrastructure — Biocon, Dr. Reddy’s, Intas, Cipla, and Serum Institute have invested billions in biologics capabilities
  • PLI Scheme for Pharmaceuticals — specific provisions for biosimilars, cell and gene therapies, and complex injectables
  • WHO NRA recognition — India’s NRA status for vaccines positions it as a credible supplier to global procurement markets
  • Make in India biologics agenda — CDSCO and DBT are actively incentivising domestic biologics development through regulatory facilitation and fast-track pathways

6. CDSCO’s Regulatory Modernisation Agenda

CDSCO’s ongoing regulatory modernisation includes:

  • Digital dossier submission — full transition to electronic CTD submissions via the SUGAM portal, enabling faster completeness checks
  • Performance-linked review timelines — defined review timelines for New Drug applications with internal performance dashboards
  • Expanded SEC/BEC scientific advisory capabilities — recruitment of additional expert members and global regulatory expert engagement
  • International regulatory collaboration — active ICMRA participation and bilateral MoUs with US, EU, and Japanese regulators progressively aligning India with global frameworks

7. Preparing for the Future: Strategic Implications

  • Monitor the 2025 Similar Biologics Guidelines revision closely — the final guidelines will reshape India’s biosimilar development pathway and create new opportunities for companies with strong analytical characterisation capabilities
  • Engage with CDSCO’s ATMP regulatory evolution proactively — companies with CAR-T or gene therapy programmes should seek pre-submission meetings to shape and understand the emerging framework
  • Invest in AI-ready regulatory data packages — begin documenting AI/ML-generated data with validation evidence meeting emerging regulatory standards
  • Position for India biologics manufacturing — evaluate whether India CMO partnerships or own-site investment fits the long-term commercial strategy
  • Build regulatory relationship capital — the future of India biological regulation will be shaped by companies that engage proactively and constructively with CDSCO and the DBT ecosystem

Conclusion

  • India’s biological regulatory landscape is being actively shaped through draft guidelines, expert committee discussions, and modernisation initiatives that will define the next decade
  • Engaging with this evolution is a strategic imperative for global biological companies 
  • India is moving toward a science-based, internationally aligned, and digitally enabled regulatory system capable of evaluating advanced biological therapies 
  • Companies that position themselves as strategic partners in this evolution will be best placed to succeed in this growing market 
  • CliniExperts Services monitors CDSCO developments in real time, engages with RCGM and DBT on emerging frameworks, and translates regulatory intelligence into actionable strategy 
  • We invite global partners to collaborate with us in navigating the future of biologicals in India

Saurangi is a food regulatory expert with 8 years of experience. She shares her knowledge and insights on regulatory updates, food trends, best practices, and news. Follow her for expert insights and practical advice on all things for food regulatory

Saurangi Shah

CliniExperts Services Pvt. Ltd.


Recent Posts

Get In Touch With Our Team

Submit your Enquiry